Aurobindo Pharma receives final USFDA nod for Risperidone syrup
September 7, 2009 – 5:33 pm | 83 views
|
Aurobindo Pharma is pleased to announce that it has received the final approval for Risperidone oral solution 1mg/ml from the US Food and Drug Administration (USFDA).
Risperidone oral solution 1mg / ml is generic equivalent to Risperdal oral solution 1mg/ml of Ortho-McNeil Janssen.
Risperidone oral solution is indicated in the treatment schizophrenia and falls under the neurological (CNS) segment. This product has a market of approximately USD 68 million for the twelve months ending March 2009 according to Newport. The product will be launched shortly.
Aurobindo now has a total of 102 ANDA approvals (74 final approvals and 28 tentative approvals) from USFDA.
Tags: according to Newport, ANDA approvals, Aurobindo Pharma, falls under the neurological, generic equivalent, launched shortly, market of approximately, Risperidone oral solution, treatment schizophrenia, US Food and Drug Administration (USFDA)
